May 2023 $111 M No. 4 $50 to $250 million 59
Renibus Therapeutics, Inc.: Raise no. 4, May 2023 × Investors in this round 59 investors had bought by the notice of Jul 17, 2025: 59 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $111 M of $111 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $148,332
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Bhupinder Jeffrey Singh · Executive Officer, Director D. Jeffrey Keyser · Executive Officer, Director Jamie Jeffrey Donadio · Executive Officer Carlos Guillem · Director Henrik Jeffrey Rasmussen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Salem Partners LLC (CRD 43363) · Los Angeles, California Sold in GA, TX Remarks in the notice On fees: “Issuer paid placement agent cash fee of 1% of aggregate amount of proceeds from sale of Series B Preferred from 06/06/2025 to 06/17/2025 and issued placement agent warrants to purchase up to 96,971 shares of Common Stock (exercise price per share, $1.61).”On the amounts: “Amounts listed include amounts from certain converting SAFEs, which may have been previously reported on Form D, and certain warrants (see Item 15). The SAFEs converted into Series B-1 Preferred Stock at the initial closing of the transaction.”Signed by D. Jeffrey Keyser, Chief Executive Officer. Newest notice filed Jul 17, 2025 (2 amendments). Read the notice at the SEC .
equity, options SEC Jul 2022 $23 M No. 3 $10 to $50 million 18
Renibus Therapeutics, Inc.: Raise no. 3, Jul 2022 × Investors in this round 18 investors had bought by the notice of Aug 22, 2022: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $23 M of $25 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them, other: "Simple Agreement for Future Equity (""SAFE"")" Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $12,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bhupinder Jeffrey Singh · Executive Officer, Director · Chief Medical Officer D. Jeffrey Keyser · Executive Officer, Director · President, Secretary and Chief Operating Officer Frank Jeffrey Stonebanks · Executive Officer, Director · Chief Executive Officer and Chairman of the Board Jamie Jeffrey Donadio · Executive Officer · Chief Financial Officer Carlos Guillem · Director Henrik Jeffrey Rasmussen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Melior Capital Management GMBH · Zug, Switzerland Sold in no state named, and outside the US Signed by Frank Stonebanks, Chief Executive Officer and Chairman of the Board. Newest notice filed Aug 22, 2022 (1 amendment). Read the notice at the SEC .
options SEC Sep 2019 $35 M No. 2 $10 to $50 million 30
Renibus Therapeutics, Inc.: Raise no. 2, Sep 2019 × Investors in this round 30 investors had bought by the notice of Feb 18, 2022: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $35 M of $35 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $116,640
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice D. Jeffrey Keyser · Executive Officer, Director · President, Secretary and Chief Operating Officer Frank Jeffrey Stonebanks · Executive Officer, Director · Chief Executive Officer Alvaro Guillem · Director · Chairman of the Board Bhupinder Jeffrey Singh · Director Henrik Jeffrey Rasmussen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Melior Capital Management GMBH · Zug, Switzerland Sold in MA, and outside the US Remarks in the notice On fees: “In addition, Recipient earned a warrant to purchase equity in the issuer with an initial value equal to 4.0% of the aggregate number of securities issued to investors introduced to issuer by Recipient”Signed by Frank Stonebanks, Chief Executive Officer. Newest notice filed Feb 18, 2022 (3 amendments). Read the notice at the SEC .
equity SEC Feb 2016 $11 M No. 1 $10 to $50 million 112
Renibus Therapeutics, Inc.: Raise no. 1, Feb 2016 × Investors in this round 112 investors had bought by the notice of May 2, 2016: 112 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $13 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carlos Guillem · Executive Officer, Director · Secretary Harpreet Kaur · Executive Officer, Director · Chairman of the Board, Chief Executive Officer and President Nels D. Bergmark · Executive Officer · Treasurer Dale Jones · Director Jennifer D. Rasmussen · Director Jocelyn D. Keyser · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Harpreet Kaur, Chairman of the Board, CEO and President. Newest notice filed May 2, 2016 (3 amendments). Read the notice at the SEC .
equity SEC